A meta-regression analysis indicated that greater improvements in BMD were strongly associated with greater reductions in fracture risk, especially in the vertebrae and hip.
Despite the relatively high prevalence of invasive oral events in women treated with denosumab, rates of osteonecrosis of the jaw remain low and tend to resolve with further therapy.
Researchers examined the associations of prevalent vertebral fracture identified on vertebral fracture assessment images in routine practice with incident fractures.
Supplementation with probiotic Lactobacillus reuteri and mucus supplements significantly prevent bone loss from consequences of postantibiotic microbial gut dysbiosis.
Results from a meta-analysis show that denosumab improved bone mineral density significantly more than bisphosphonates at the lumbar spine, total hip, and femoral neck.
Both high and low niacin intake was associated with a risk for incident hip fractures in older adults.
Measuring serum estradiol during the menopausal transition might help identify women at higher risk for fractures.
Bone mineral density measures were significantly greater at 3 years in postmenopausal women with comorbid osteoporosis and rheumatoid arthritis who were given vitamin D and calcium supplementation.
In the Biologics License Application (BLA) resubmission, Amgen and UCB proposed to narrow the indication to treatment of osteoporosis in postmenopausal women at high risk of fracture.
The presence of primary hypertension does not appear to have an effect on the prognosis of postmenopausal osteoporosis.
Gender-affirming hormonal treatment does not negatively affect bone mineral density in transgender people.